CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
Zacks.com on MSN5d
TSVT, BMY Discontinue Enrollment in Late-stage Abecma StudyTSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...
Shares of 2seventy bio (NASDAQ:TSVT) lost ~16% in the premarket Wednesday after the cancer drug developer and its partner ...
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment ...
“With a greatly improved NDMM treatment landscape and following our rigorous review of the business case for the KarMMa-9 study, we have decided to discontinue enrollment in this Phase 3 study ...
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment in Phase 3 KarMMa-9 study evaluating Abecma with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback